4.1 Review

The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19

期刊

EUROPEAN JOURNAL OF PEDIATRIC SURGERY
卷 31, 期 4, 页码 326-334

出版社

GEORG THIEME VERLAG KG
DOI: 10.1055/s-0041-1731294

关键词

extracellular vesicles; ARDS; mesenchymal stem cells; nanoparticles; vaccine

资金

  1. Hospital for Sick Children (SickKids start-up funds)

向作者/读者索取更多资源

Exosomes have emerged as a potential strategy for the treatment of COVID-19, showing promising roles in anti-inflammatory, immunomodulatory, convalescent plasma therapy, and drug delivery. Their advantageous aspects, such as endogenous origin, ability to cross biological barriers, high stability in circulation, low toxicity, and immunogenicity have led to their extensive research and application in the treatment and diagnosis of COVID-19, as well as guiding their potential use in other clinical conditions.
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), continues to be a major health concern. In search for novel treatment strategies against COVID-19, exosomes have attracted the attention of scientists and pharmaceutical companies worldwide. Exosomes are small extracellular vesicles, secreted by all types of cells, and considered as key mediators of intercellular communication and stem-cell paracrine signaling. Herein, we reviewed the most recent literature about the role of exosomes as potential agents for treatment, prevention, diagnosis, and pathogenesis of COVID-19. Several studies and ongoing clinical trials have been investigating the anti-inflammatory, immunomodulatory, and reparative effects of exosomes derived from mesenchymal stem/stromal cells for COVID-19-related acute lung injury. Other studies reported that exosomes play a key role in convalescent plasma therapy for COVID-19, and that they could be of use for the treatment of COVID-19 Kawasaki's-like multisystem inflammatory syndrome and as drug delivery nanocarriers for antiviral therapy. Harnessing some advantageous aspects of exosome biology, such as their endogenous origin, capability of crossing biological barriers, high stability in circulation, and low toxicity and immunogenicity, several companies have been testing exosome-based vaccines against SARS-CoV-2. As they carry cargos that mimic the status of parent cells, exosomes can be isolated from a variety of sources, including plasma, and employed as biomarkers of COVID-19. Lastly, there is growing evidence supporting the role of exosomes in COVID-19 infection, spread, reactivation, and reinfection. The lessons learned using exosomes for COVID-19 will help determine their efficacy and applicability in other clinical conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据